Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page

Heart failure patients benefit from MitraClip therapy, PERMIT-CARE trial shows

Wednesday, 05 Oct 2011 14:41
Angelo Auricchio
Angelo Auricchio

Results of an observational study presented at the European Society of Cardiology meeting in Paris demonstrate that the percutaneous catheter-based MitraClip treatment improves symptoms and promotes reverse left ventricular remodeling in patients with mitral regurgitation, who do not respond to cardiac resynchronisation therapy (CRT).

The trial, called PERMIT-CARE, is an investigator-led study evaluating the safety and efficacy of MitraClip treatment in 51 patients with clinically significant functional mitral regurgitation at seven European centres. All patients had unchanged symptoms and unchanged left ventricular volumes after at least six months of CRT. Nearly all patients enrolled in the study were considered ineligible for mitral valve surgery due to a high estimated mortality risk.

Results of the study demonstrate that functional mitral regurgitation reduction with MitraClip treatment is feasible, safe, and leads to substantial improvement in NYHA functional class and reverse left ventricular remodeling in approximately 70% of patients.

“Results of this study suggest that MitraClip treatment could offer, for the first time, a solution for heart failure patients who have severe mitral regurgitation and are unresponsive to CRT,” said Angelo Auricchio, the study’s lead investigator, of the Division of Cardiology at the Fondazione Cardiocentro Ticino in Lugano, Switzerland. “Surgery is not a good option for these patients because of their advanced left ventricular dysfunction and low ejection fraction. We have shown that they were significantly improved following treatment with the MitraClip device. I look forward to additional prospective studies to confirm our findings and to evaluate appropriate timing of MitraClip treatment in heart failure patients.” 


Severe functional mitral regurgitation is common in heart failure patients, including approximately one-third of those indicated for CRT therapy. CRT often reduces mitral regurgitation; however, mitral regurgitation has been reported to persist in about 20–25% of CRT treated patients, and in an additional 10–15% mitral regurgitation may actually worsen after CRT treatment.

Results of the study will be published in an upcoming issue of the Journal of the American College of Cardiology. The MitraClip system is designed to reduce significant mitral regurgitation by clipping together the leaflets of the mitral valve, one of the four valves of the heart. The catheter-based MitraClip device is delivered to the heart through the femoral vein, a blood vessel in the leg. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. After treatment, patients are usually home within two to three days and have been observed to recover quickly. The safety and efficacy of the MitraClip system were evaluated in the EVEREST II randomised clinical trial.

Add New Comment

Related Items

Most popular

Long-term results of RESPECT indicate that PFO closure may be effective at preventing recurrent stroke
Friday, 16 Oct 2015
The long-term study results from the RESPECT trial found that closing a patent foramen ovale (PFO) with an Amplatzer PFO Occluder was superior to medical management in the prevention of recurrent ... Long-term results of RESPECT indicate that PFO closure may be effective at preventing recurrent stroke

Custom-designed vascular training model now available at events
Thursday, 05 Nov 2015
The ThinkRadial Vascular Training Model provides realistic simulation to several procedurally critical vascular destinations, while allowing the practitioner to “see” the way radial products perform ... Custom-designed vascular training model now available at events

Friday, 16 Oct 2015
Edwards Lifesciences has announced a one-year survival rate of 89.3% for high-risk patients who received the Edwards Sapien 3 transcatheter aortic valve via transfemoral, as well as low rates of ... Edwards Sapien 3 valve demonstrates high survival and low stroke rate at one year


Helping Little Hearts to mend
Friday, 27 Nov 2015
Nurun Nahar Fatema talks about how Muntada Aid’s Little Hearts campaign has helped children in Bangladesh with congenital heart problems. Helping Little Hearts to mend

An interventional cardiologist’s view on left atrial appendage closure
Thursday, 12 Nov 2015
Martin W Bergmann is an interventional cardiologist working in Germany, who performs percutaneous LAA closure procedures. He explores why there is still a need for such procedures even in the era of ... An interventional cardiologist’s view on left atrial appendage closure


Corrado Tamburino
Tuesday, 20 Oct 2015
Corrado Tamburino (full professor of Cardiology, Ferrarotto & Policlinico Hospitals, University of C... Corrado Tamburino

Javier Escaned
Wednesday, 02 Sep 2015
Javier Escaned (head of Section, Interventional Cardiology Unit, Hospital Clinico San Carlos, M... Javier Escaned

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions